Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Photo illustration of a group of weight loss medications on a white background.Ucg | Universal Images Group | Getty ImagesThe...
iShares U.S. Healthcare ETF
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
The Eli Lilly and Novo Nordisk logos.Mike Blake | Tom Little | ReutersEvery time Novo urges investors to look ahead,...
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The U.S. Food and Drug Administration approved Eli Lilly's GLP-1 pill, the company said, a major milestone for the Indianapolis-based...
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients,...
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025.Kyle Grillot | Bloomberg | Getty...
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting...
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.Shelby...
